Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

This observational study is looking at immune cells called Myeloid-Derived Suppressor Cells (MDSCs) in people with breast cancer. Researchers want to understand how these MDSCs, which are considered "unfavorable" immune cells, might stop "favorable" immune cells called Natural Killer Cells from working properly. You might be able to join if you are 18 or older, can give informed consent, and have Stage I-III breast cancer. The study involves collecting specimens from you. The goal is to see how strongly MDSCs inhibit Natural Killer Cells, with measurements taken for up to one year. The study plans to enroll 99 participants, but its current status is unclear.

Study design
This is an observational study planning to enroll 99 participants. It does not involve a specific treatment intervention.
What's involved
You would provide specimens, which are obtained from patients being treated for breast cancer.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured for up to one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04022616

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

Recruiting
Not specifiedAges 18+Observational
Ohio State University Comprehensive Cancer Center
~99 participants
Updated 2026-04-06 on ClinicalTrials.gov
What's tested:Specimen collection

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Isolate unfavorable immune cells MDSC from the peripheral blood or tumors of study subjects and test how strongly they inhibit function of favorable immune cells called Natural Killer Cells.
Measured over up to 1 year
Breast Cancer
1 sites across 1 states
Ohio1
  • William Carson, MD · PRINCIPAL_INVESTIGATOR · Ohio State Comprehensive Cancer Center
Ohio State Comprehensive Cancer Center
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years of age or older
Ability to give informed consent
Stage I-III breast malignancy

Exclusion

Unable to tolerate venipuncture
  • Isolate unfavorable immune cells MDSC from the peripheral blood or tumors of study subjects and test how strongly they inhibit function of favorable immune cells called Natural Killer Cells.up to 1 year

    Function of Natural Killer Cells will be studied by measuring their ability to kill target cancer cells coated with monoclonal antibodies. isolate unfavorable immune cells called Myeloid Derived Suppressor Cells (MDSC) from the peripheral blood or the tumors of study subjects and test how strongly they inhibit function of favorable immune cells called Natural Killer Cells. Function of Natural Killer Cells will be studied by measuring their ability to kill target cancer cells coated with monoclonal antibodies.